PLA2G10
Group 10 secretory phospholipase A2
As of the edition of 20 October 2026, PLA2G10 (group 10 secretory phospholipase A2, UniProt O15496) has 1 drug tested at it and 2 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O15496
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 7
- Disease areas
- Heart and blood vessels; Chemically induced; Injuries; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 7
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Varespladib methyl | Stopped | Phase 3 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Anthera Pharmaceuticals | Route A |
The other 1 company at PLA2G10
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at PLA2G10, ranked, with the facts behind eachRequest access. Nothing is shown until you do.